MY33-3

MY33-3 is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ , with an IC 50 of ~0.1 μM. MY33-3 also inhibits PTP-1B ( IC 50 ~0.7 μM). MY33-3 can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction In Vitro MY33-3 (1 μM; pretreated for 5 min) blocks Ethanol-induced activation of TrkA and ALK in SH-SY5Y cells. MY33-3 (0.1-10 μM; 24 h) limits LPS-induced nitrites production and iNos increases in BV2 microglial cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SH-SY5Y cells Concentration: 1 μM Incubation Time: Pretreated for 5 min and co-treated for 15 min Result: Decreased the Ethanol-induced activation of TrkA and ALK. None of the treatments significantly changed total TrkA or total ALK protein levels. In Vivo MY33-3 (60 mg/kg; p.o. on days 3 and 4) reduces ethanol consumption when comparing day 2 with day 3. MY33-3 reduces preference for the ethanol solution on day 3 . MY33-3 (i.p.) reverses the Sevoflurane-induced decrease in the discrimination index and impaired motor learning ability. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J mice (8-10 weeks of age) are received two-bottle drinking in the dark (DID) procedure using 20% ethanol Dosage: 60 mg/kg Administration: P.o. 1 hour before the drinking session in the DID test on days 3 and 4 Result: Reduced ethanol consumption when comparing day 2 with day 3. Showed a reduced preference for the ethanol solution. Not affected total fluid consumption. Form:Solid IC50& Target:IC50: 0.1 μM (RPTPβ/ζ), 0.7 μM (PTP-1B)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet